

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Tsunetoshi Honma et al.  
Entitled: A PHARMACEUTICAL COMPOSITION COMPRISING A DUAL  
ANTAGONIST AGAINST PGD<sub>2</sub>/TXA<sub>2</sub> RECEPTORS HAVING A [2.2.1]  
OR [3.1.1] BICYCLIC SKELETON  
Serial No. To be assigned  
Filing Date Concurrently

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Prior to examination of the present application, Applicant's respectfully requests that the above-identified application be amended as follows:

**In the Claims:**

In accordance with 37 C.F.R. § 1.121(c) (3), please substitute for pending claims 12-19 with the following clean version of the claims. The changes to these claims are shown explicitly in the attached "Marked Up Version of Claims."

12. (Amended) The compound according to claim 8 wherein X<sup>2</sup> is a bond, -CH<sub>2</sub>-, -S-, -SO<sub>2</sub>-, -CH<sub>2</sub>O-, -O-CH<sub>2</sub>-, -CH<sub>2</sub>-S- or -S-CH<sub>2</sub>-, the prodrug, the pharmaceutically acceptable salt, the hydrate thereof.

13. (Amended) The compound according to claim 8 wherein R<sup>1</sup> is -CH<sub>2</sub>-CH=CH-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>-COOH, m is 0, and p is 0, the prodrug, the pharmaceutically acceptable salt, the hydrate thereof.

14. (Amended) A pharmaceutical composition which comprises a compound according to claim 8.

15. (Amended) A pharmaceutical composition having a dual antagonistic activity against PGD<sub>2</sub>/TXA<sub>2</sub> receptors which comprises a compound according to claim 8.

16. (Amended) The pharmaceutical composition comprising a compound according to claim 14, which is used for asthma.

17. (Amended) The pharmaceutical composition comprising a compound according to claim 14, which is used for nasal blockage.

18. (Amended) Use of the compound according to claim 8 for manufacturing a pharmaceutical composition for asthma or nasal blockage.

19. (Amended) A method for treating asthma or nasal blockage which comprises administering the compound according to claim 8.

**REMARKS**

Applicant respectfully requests that the foregoing amendments be made prior to examination of the present application.

Respectfully submitted,

Date September 10, 2001

By Phillip J. Artavia

Reg. No.  
38,819

FOLEY & LARDNER  
3000 K Street, N.W., Suite 500  
Washington, D.C. 20007-5109  
Telephone: (202) 672-5571  
Facsimile: (202) 672-5399

for / Stephen B. Maebius  
Attorney for Applicant  
Registration No. 35,264